Kneat Recognised as Leader in G2 Pharma and Biotech Fall 2025 Grid Reports

Rhea-AI Summary

Kneat (OTCQX: KSIOF), a leader in validation and quality process digitization, has achieved top rankings in G2's Fall 2025 Pharma and Biotech Software category reports. The company secured leadership positions in three categories with an impressive G2 Satisfaction Score of 98/100, surpassing the second-ranked company by 20 points.

The company earned leadership recognition in the Grid® Report, Relationship Index, and Mid-Market Grid® Report for Pharma and Biotech. Additionally, Kneat ranked second in the G2 Pharma and Biotech Usability Index, demonstrating strong performance in administration, ease of use, and requirements fulfillment.

Positive

• Achieved exceptional G2 Satisfaction Score of 98/100, outperforming competitors by 20 points
• Secured leadership position in three major G2 software category reports
• Strong performance in customer relationship metrics including ease of doing business and support quality
• High ranking in usability metrics, indicating strong product market fit

Negative

• None.

Score based on User Satisfaction and Market Presence significantly exceeds peers

Limerick, Ireland--(Newsfile Corp. - September 24, 2025) - kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, has been awarded the top position in three of G2 Software Review's Fall 2025 Pharma and Biotech Software category reports. Kneat was recognized as:

• Leader in the Grid® Report for Pharma and Biotech
• Leader in the Relationship Index for Pharma and Biotech
• Leader in the Mid-Market Grid® Report for Pharma and Biotech.

Kneat achieved a total G2 Satisfaction Score of 98 out of 100, 20 points higher than the second-ranked company's score of 78.

Grid from Fall 2025 G2 Grid® Report for Pharma and Biotech

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11876/267637_kneatimg1.jpg

"Earning three G2 leader badges is no small feat for a software company supporting any industry, let alone one as demanding and precise as life sciences," said Eddie Ryan, CEO of Kneat. "The achievement reflects not only the trust that our customers place in us, but the dedication of our team to deliver Kneat's pioneering user-focused software. At Kneat, customer satisfaction isn't just a value — it's at the heart of everything we do. I am proud of our team for embracing this mission every single day."

Kneat's top rating in the G2 Pharma and Biotech Relationship Index is based on customer feedback across categories "Ease of Doing Business," "Likely to Recommend," and "Quality of Support." Kneat was also rated 2^nd overall in the G2 Pharma and Biotech Usability Index measuring customer feedback on "Ease of Admin," "Ease of Use" and "Meets Requirements."

G2 scores are based on validated reviews from industry professionals utilising factors such as a company's review count, web presence, growth, influence and engagement. As the largest and most trusted software marketplace, G2 offers 100% validated reviews that more than a million professionals annually — including employees at all Fortune 500 companies — rely on to make informed decisions about their software purchases.

About Kneat

Kneat Solutions provides leading companies in highly regulated industries with unparalleled efficiency in validation and compliance through its digital validation platform Kneat Gx. As an industry leader in customer satisfaction, Kneat boasts an excellent record for implementation, powered by our user-friendly design, expert support, and on-demand training academy. Kneat Gx is an industry-leading digital validation platform that enables highly regulated companies to manage any validation discipline from end-to-end. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. compliance standard. Independent customer studies have shown Kneat Gx to reduce labor hours associated with validation documentation by more than 50%, accelerate review and approval cycles by up to 50%, and consistently support higher standards of regulatory compliance. For more information visit www.kneat.com.

For further information:

Katie Keita, Kneat Investor Relations
P: + 1 902-450-2660
E: investors@kneat.com 

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267637

FAQ

What recognition did Kneat (KSIOF) receive in the G2 Fall 2025 reports?

Kneat received leadership recognition in three categories: the Grid® Report, Relationship Index, and Mid-Market Grid® Report for Pharma and Biotech, with a top G2 Satisfaction Score of 98/100.

How did Kneat's G2 satisfaction score compare to competitors in Fall 2025?

Kneat achieved a satisfaction score of 98/100, which was 20 points higher than the second-ranked company's score of 78.

What specific areas did Kneat excel in according to the G2 Fall 2025 reports?

Kneat excelled in the Relationship Index categories of Ease of Doing Business, Likely to Recommend, and Quality of Support, while also ranking 2nd in the Usability Index.

How does G2 determine its software rankings and scores?

G2 bases its scores on validated reviews from industry professionals, considering factors such as review count, web presence, growth, influence, and engagement from over a million professionals including Fortune 500 employees.